Published in PLoS One on March 29, 2016
Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet (2016) 0.77
Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments. J Neurol (2016) 0.76
Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis (2017) 0.75
Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A (1976) 21.06
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol (1985) 3.83
Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron (2006) 3.51
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40
Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol (2006) 2.33
Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A (1996) 2.32
Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res (1993) 2.29
The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet (2002) 2.25
Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase. Proc Natl Acad Sci U S A (1993) 1.95
Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med (2009) 1.94
Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol (2004) 1.92
Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 1.87
The four ages of Down syndrome. Eur J Public Health (2006) 1.85
Phenotype associated with APP duplication in five families. Brain (2006) 1.83
Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A (2001) 1.72
Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev (2007) 1.69
Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev (2007) 1.67
A prospective study of Alzheimer disease in Down syndrome. Arch Neurol (1989) 1.64
Dementia and mortality in persons with Down's syndrome. J Intellect Disabil Res (2006) 1.48
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology (2014) 1.47
The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci (2009) 1.46
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry (2002) 1.42
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet (2010) 1.41
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.41
Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J Comp Neurol (2009) 1.31
Immunology of Down syndrome: a review. Am J Med Genet Suppl (1990) 1.30
Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem (2007) 1.27
Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One (2010) 1.23
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A (2007) 1.17
Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci (2012) 1.17
Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J Neurosci (2013) 1.13
Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis (2011) 1.09
Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome (2011) 1.08
Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol (2011) 1.03
Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging (2006) 1.01
TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. Blood (2012) 0.96
Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiol Aging (2004) 0.93
A safer vaccine for Alzheimer's disease? Neurobiol Aging (2002) 0.93
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. Drug Des Devel Ther (2014) 0.93
Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement (2014) 0.90
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Int J Geriatr Psychiatry (2004) 0.86
Inflammatory and Immunological parameters in adults with Down syndrome. Immun Ageing (2011) 0.85
Aging and down syndrome. Curr Gerontol Geriatr Res (2012) 0.85
A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One (2015) 0.84
Down's syndrome, longevity, and Alzheimer's disease. Br J Psychiatry (1993) 0.78
Iron overload in reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations. AJR Am J Roentgenol (1997) 0.78
Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues. PLoS One (2015) 0.77
The pulse of drug development for Alzheimer's disease. Rev Recent Clin Trials (2010) 0.76
Chromosome 21 and Down syndrome: the post-sequence era. Cold Spring Harb Symp Quant Biol (2003) 0.76